40
Participants
Start Date
December 31, 2004
Study Completion Date
March 31, 2006
M200 (volociximab) in Combination with Dacarbazine (DTIC)
Palmetto Hematology Oncology, P.C., Spartanburg
MD Anderson Cancer Center, Houston
Arizona Cancer Center, Tucson
UCLA School of Medicine, Los Angeles
Cancer Institute Medical Group, Inc., Santa Monica
University of Alabama at Birmingham-Comprehensive Cancer Ctr., Birmingham
University of Pittsburgh, Pittsburgh
Lead Sponsor
PDL BioPharma, Inc.
INDUSTRY